Results 51 to 60 of about 115,857 (253)

Breakthroughs in myeloproliferative neoplasms

Hematology, 2012
The discovery of the JAK2V617F mutation ushered the field of Philadelphia-negative myeloproliferative neoplasms (MPNs) into the era of targeted therapy. Currently, there are several JAK2 inhibitors in clinical trials for patients with MPNs, particularly for patients with myelofibrosis (MF).
Fabio P S, Santos, Srdan, Verstovsek
openaire   +2 more sources

Referral Patterns and Diagnostic Timeliness in Pediatric Cancer: A Hospital‐Based Study in Indonesia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Timely diagnosis and treatment are critical for improving survival among children with cancer. In low‐ and middle‐income countries (LMICs), delays are common and may be influenced by fragmented referral pathways and diagnostic limitations.
Nur Melani Sari, Regina Hadi Putri, Fatimah Assyifa, Judith Spijkerman, Gertjan Johannes Kaspers, Susi Susanah   +5 more
wiley   +1 more source

Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases

Haematologica, 2012
We analyzed 636 patients with diverse myeloproliferative neoplasms or myelodysplastic/myeloproliferative neoplasms for mutations of the Casitas B-cell lymphoma gene (CBLmut) in exons 8 and 9 and performed correlations to other genetic alterations. CBLmut
Susanne Schnittger, Ulrike Bacher, Tamara Alpermann, Andreas Reiter, Madlen Ulke, Frank Dicker, Christiane Eder, Alexander Kohlmann, Vera Grossmann, Andreas Kowarsch, Wolfgang Kern, Claudia Haferlach, Torsten Haferlach   +12 more
doaj   +1 more source

Pathogenesis of myeloproliferative neoplasms

Experimental Hematology, 2015
Major progress has been recently made in understanding the molecular pathogenesis of myeloproliferative neoplasms (MPN). Mutations in one of four genes-JAK2, MPL, CALR, and CSF3R-can be found in the vast majority of patients with MPN and represent driver mutations that can induce the MPN phenotype.
Skoda, Radek C., Duek, Adrian, Grisouard, Jean   +2 more
openaire   +4 more sources

Identifying Patterns of Hospitalizations Among Childhood Cancer Survivors: A Population‐Based Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Childhood cancer survivors (CCSs) experience more hospitalizations than the general population. We aimed to identify distinct hospitalization patterns among Queensland CCSs and the associated characteristics. Methods Cases (aged ≤14 years) diagnosed between 1995 and 2019 while residents of Queensland were identified through the ...
Hai Pham, Teyl Engstrom, Peter Baade, Natalie Bradford, Sarah Pont, Louise Marquart‐Wilson, Natasha Nassar, Jason D. Pole   +7 more
wiley   +1 more source

Leveraging big data and artificial intelligence for smarter trials in myeloproliferative neoplasms

Frontiers in Hematology
The myeloproliferative neoplasms (MPNs) – polycythemia vera, essential thrombocytosis, and primary myelofibrosis – are chronic blood cancers that originate from hematopoietic stem cells carrying driver mutations which activate cytokine signaling pathways
Joshua W. Bliss, Spencer Krichevsky, Spencer Krichevsky, Joseph Scandura, Ghaith Abu-Zeinah   +4 more
doaj   +1 more source

Molecular approach to diagnose BCR/ABL negative chronic myeloproliferative neoplasms

Revista Brasileira de Hematologia e Hemoterapia, 2011
Chronic myeloproliferative neoplasms arise from clonal proliferation of hematopoietic stem cells. According to the World Health Organization myeloproliferative neoplasms are classified as: chronic myelogenous leukemia, polycythemia vera, essential ...
Michelle Maccarini Barcelos, Maria Cláudia Santos-Silva   +1 more
doaj   +1 more source

Circular RNA expression landscapes in myelodysplastic neoplasms: Associations with mutational signatures and disease progression

Molecular Oncology, EarlyView.
In this explorative study, the abundance of circular RNA molecules in bone marrow stem cells was found to be elevated in patients with high‐risk myelodysplastic neoplasms, and to be associated with an increased risk of progression to acute myeloid leukemia.
Eileen Wedge, Morten Tulstrup, Gabriele Todisco, Pedro Moura, Christophe Côme, Jakob Werner Hansen, Jakob Schmidt Jespersen, Balthasar Schlotmann, Maria Creignou, Mette Dahl, Claudia Schöllkopf, Klas Raaschou‐Jensen, Krister Wennerberg, Bo Porse, Joachim Weischenfeldt, Eva Hellström‐Lindberg, Lasse Sommer Kristensen, Kirsten Grønbæk   +17 more
wiley   +1 more source

Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms

Haematologica, 2013
Most DNA methylation studies in classic Philadelphia-negative myeloproliferative neoplasms have been performed on a gene-by-gene basis. Therefore, a more comprehensive methylation profiling is needed to study the implications of this epigenetic marker in
Cristina Pérez, Marien Pascual, José Ignacio Martín-Subero, Beatriz Bellosillo, Victor Segura, Eric Delabesse, Sara Álvarez, María José Larrayoz, José Rifón, Juan Cruz Cigudosa, Carles Besses, María José Calasanz, Nicholas C.P. Cross, Felipe Prósper, Xabier Agirre   +14 more
doaj   +1 more source

JAK2 mutations in myeloproliferative neoplasms [PDF]

, 2009
Deep insight on JAK2 mutations in myeloproliferative ...
Gangat, N, Tefferi, A
core   +1 more source